Introduction
Melatonin, also known as N-acetyl-5-methoxytryptamine, is an indole amine produced and released by the pineal gland mainly during the dark phase of the light/dark cycle (Bubenik, 2008) . It is also produced in many other tissues but it is not released to the blood from these sites (Jarzynka et al., 2009) . Melatonin has been found to be involved in a number of processes, including circadian rhythm, tumor growth inhibition, immune response, and reproduction, as well as scavenging of free radicals. Moreover, metabolites of melatonin are also highly effective radical scavengers (Galano et al., 2013) .
Melatonin regulates the differentiation of stem cells. It enhances osteogenic differentiation of several cell types such as human osteoblasts, human mesenchymal stem cells (hMSCs), human bone cells, and MC3T3-E1 preosteoblast and rat osteoblast-like osteosarcoma 17/2.8 cells, as well as bone formation and growth in mice (Roth et al., 1999; Satomura et al., 2007; Zhang et al., 2010) . Melatonin enhances cartilage matrix synthesis as well as the expression of chondrogenic markers including collagen II, Sox 9, and aggrecan of porcine articular chondrocytes. Recently, it was found that it increases chondrogenic differentiation of hMSCs (Pei et al., 2009) . In contrast to osteogenesis and chondrogenesis, melatonin has been reported to inhibit adipogenic differentiation of hMSCs. It inhibits triglyceride accumulation in rat osteoblast-like ROS17/2.8 cells as well as increasing the expression of leptin in rat adipocytes (Brydon et al., 2001) . Additionally, in vivo, reduced lipolysis and increased lipogenesis were found in pinealectomized rats, mimicked by the withdrawal of melatonin (Borges-Silva et al., 2005) . Although melatonin's effect on osteogenic, chondrogenic, and adipogenic differentiations has been described, data regarding the effects of melatonin on other cell functions such as neurogenesis, myogenesis, and odontogenesis are limited or not known. Melatonin concentrations have a modulatory effect on both selfrenewal and neural differentiation of neural stem cells (Moriya et al., 2007) . In addition, it stimulates neural stem cells to differentiate into dopaminergic neurons in rats (Kong et al., 2008) . Melatonin plays a protective role on the survival of myocytes against damage by doxorubicin and reduces the hypoxic damage in cardiomyocytes (Salie et al., 2001; Xu and Ashraf, 2002) . Although melatonin's effect on odontogenesis remains unclear, it is likely to have an important role in tooth development since melatonin receptor MT 1 has been found in the tooth germs of human and mice (Kumasaka et al., 2010) .
Human tooth germ stem cells (hTGSCs) are mesenchymal stem cells with high proliferation and differentiation capacity that are derived from human third molar tooth germs of young individuals (Yalvac et al., 2010) . Besides their availability in adults and the lack of ethical issues, hTGSCs can be converted into osteogenic, adipogenic, and odontogenic cells (Gronthos et al., 2002; Güven et al., 2013; and also endothelial linages .
In the present study, the effect of melatonin on osteo-, chondro-, adipo-, neuro-, myo-, and odontogenic differentiation of hTGSCs was evaluated. The aim of this study was to identify the role of melatonin on various differentiations of hTGSCs and to provide additional evidence for the use of melatonin as a drug in regenerative medicine.
Materials and methods

Isolation and culture conditions of hTGSCs
Human tooth germs were collected from the third molar teeth of patients 14-18 years old. The collected tooth germs were harvested and minced (Taşlı et al., , 2015 . The tooth germ tissue was plated in six-well plates (BIOFIL, TCP, Switzerland) and grown to confluency in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) prostatespecific antigen (PSA) (10,000 units/mL penicillin, 10,000 µg/mL streptomycin, 25 µg/mL amphotericin B) (Invitrogen, GIBCO, UK). The harvested cells expanded and started to appear after 3-4 days, and they covered the surface after 8 days. Thereafter, the cells were trypsinized using 0.25% (v/v) trypsin/EDTA (Invitrogen, GIBCO). Medium was added to detached cells to inhibit the activity of trypsin. After the cells were centrifuged at 300 × g for 5 min at room temperature, the pellet was dissolved in fresh medium and seeded in a T-75 flask (Zelkultur Flaschen, Switzerland). The cells were maintained at 37 °C and 5% CO 2 in a humidified incubator. Cells from passages 3-4 were used in all experiments.
Characterization of hTGSCs
The procedure for characterization of hTGSCs was previously published by our group (Yalvac et al., 2010) . Cells were trypsinized and incubated with the primary antibodies, which were prepared in PBS. For characterization, primary antibodies against CD29, CD34, CD45, CD90, CD105, CD133, CD166 (Santa Cruz Biotechnology Inc., USA), and CD73 (Zymed, USA) were used. The cells were washed with PBS to remove the excess primary antibodies. Thereafter, the cells were incubated with fluorescein-isothiocyanate (FITC)-conjugated secondary antibody at 4 °C for 1 h except for CD29, for which phycoerythrin (PE)-red light-harvesting protein containing chromophore-conjugated monoclonal antibody was used. The flow cytometry analysis of the cells was performed by using the Becton Dickinson FACSCalibur flow cytometry system (Becton Dickinson, USA).
MTS Assay
Melatonin (MP Biomedicals LLC, USA) at different concentrations (50 nM, 100 nM, and 150 nM) was prepared in DMEM with 10% (v/v) FBS and 1% (v/v) PSA. Cells were seeded on a 96-well plate (BIOFIL, TCP, Switzerland) at a density of 5000 cells per well. The following day, cells were treated with different concentrations of melatonin and 20% (v/v) DMSO. Cell viability was measured by the MTS assay (CellTiter96 Aqueous One Solution, Promega, UK) according to the manufacturer's instructions. MTS (3-(4,5-dimethyl-thiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium) is a yellow tetrazolium salt that is catabolized to formazan by dehydrogenase enzyme in mitochondria of living cells. Formazan is a purple compound and the detection in this assay is based on the measurement of formazan compounds by an ELISA plate reader. After incubating the cells with melatonin for 24, 48, and 72 h, 10 µL of MTS reagent and 100 µL of DMEM were added to the cells followed by incubation for 2 h. Thereafter, the absorbance at 490 nm was measured by an ELISA plate reader (BioTek Instruments, Inc., USA). 2.4. Differentiation process hTGSCs were induced to differentiate into osteogenic, neurogenic, adipogenic, chondrogenic, odontogenic, and myogenic cells. The cells were seeded on a six-well plate for RNA isolation and a 48-well plate (BIOFIL, TCP) for immunocytochemistry at a density of 150,000 cells/well and 10,000 cells/well respectively for each differentiation. For osteogenic differentiation the cells were seeded on six-well plates followed by the addition of osteogenic differentiation medium, which consisted of DMEM, 10% (v/v) FBS, 0.1 µM dexamethasone (AppliChem, Germany), 10 mM β-glycerol phosphate (Sigma, USA), and 50 µg/mL ascorbic acid (Sigma) (Taşlı et al., 2013a) , with or without 100 nM melatonin. The medium was changed every other day and the cells were treated with the osteogenic differentiation medium for 14 days. For adipogenic differentiation, the cells were induced to differentiate into adipocytes using a previously published method (Lu et al., 2009) . The cells were seeded on a six-well plate and given adipogenic differentiation medium, which is composed of DMEM, 10% (v/v) FBS, 1 µM dexamethasone, 100 µM indomethacin (Sigma), 500 µM IBMX (Calbiochem, Merck Millipore, Germany), and 0.01 mg/mL insulin (GIBCO), with or without melatonin. Adipogenic differentiation lasted 10 days in the adipogenic differentiation medium that was changed every other day. In the neurogenic differentiation experiments, a modification of a previously published method was used for neural induction. hTGSCs were treated with a medium including DMEM, 10% (v/v) FBS, 200 µM butylated hydroxyanisole (Sigma), 5 mM KCl, 2 µM valproic acid (Sigma), and 5 g/mL insulin for 14 days with the medium changed every 3 days, with or without melatonin. A modification of a previous method was used for chondrogenic differentiation. The chondrogenic differentiation medium consisted of DMEM supplemented with 10% (v/v) FBS, 0.1 µM dexamethasone, 10 ng/mL TGF-β1 (Sigma), 50 mg/mL ITS (GIBCO), 5.35 mg/mL linoleic acid (Acros Organics, Belgium), and 6.25 µg/mL insulin, with or without melatonin. The chondrogenic differentiation lasted for 3 weeks, changing the medium every 2-3 days. The odontogenic differentiation was conducted by treating the cells with differentiation medium containing DMEM, 10% (v/v) FBS, 10 -8 M dexamethasone, 5 mmol/L KH 2 PO 4 , and 50 µg/mL ascorbic acid, with or without melatonin (Taşlı et al., 2013a) . Eventually, myogenic differentiation was done with DMEM medium supplemented with 5% (v/v) horse serum, 0.1 µM dexamethasone, and 50 µM hydrocortisone (Sigma) (Taşlı et al., 2013b) . The myogenic differentiation took 3 weeks with medium changed every 2-3 days. Positive control groups were treated with the respective differentiation mediums while negative control groups were cultured only in DMEM supplemented with 10% (v/v) FBS and 1% (v/v) PSA.
Alkaline phosphatase activity assay
Alkaline phosphatase (ALP) activity was determined to demonstrate osteogenic differentiation. After the process of osteogenic differentiation, medium was removed and cells were treated with 0.2% (w/v) Triton X-100 (BioBasic Inc., Canada) for lysis. Cells were collected from plates and mixed by vortex for 20 min at room temperature. Thereafter, 10 µL of cell lysate was added to each well of a 96-well plate followed by the addition of 90 µL of ALP solution (BioAssay Systems, USA). After incubation for 15 min, the absorbance at 405 nm was measured by an ELISA plate reader.
Von Kossa staining
Von Kossa staining is a method based on the detection of calcium or calcium salt deposits. Cells were seeded on six-well plates at a concentration of 50,000 cells/ well. At the end of both osteogenic and odontogenic differentiation, the medium was removed and the cells were washed three times with PBS. The cells were then incubated with paraformaldehyde for 20 min for fixation. After the addition of 3% (w/v) silver nitrate, the cells were exposed to UV light for 1 h at room temperature. After washing the cells three times with PBS, 5% (w/v) sodium thiosulfate was added to each well followed by incubation for 2 min at room temperature. After the incubation, the cells were again rinsed three times with PBS. Thereafter, the cells were incubated with nuclear fast red for 5 min at room temperature. After washing with PBS, the cells were observed under a light microscope (Güven et al., 2013) .
Oil red O staining
Oil red oil solution was prepared by dissolving 0.5 g of oil red oil (Sigma, USA) in 100 mL of isopropanol. The cells were then fixed with 2% (w/v) paraformaldehyde for 30 min followed by washing three times with PBS. The cells were then incubated with oil red oil solution diluted 6:4 in PBS for 1 h for staining. Cells were washed with PBS and observed under a light microscope (Doğan et al., 2012) .
Alcian blue staining
One gram of alcian blue dye (Sigma) was dissolved in 100 mL of 3% (w/v) acetic acid to prepare the alcian blue staining solution. The cells were fixed with 2% paraformaldehyde for 30 min and incubated with alcian blue staining solution for 30 min. After the incubation, the cells were washed three times with PBS and the samples were observed under a light microscope (Taşlı et al., 2013c) .
Immunocytochemistry
At the end of the differentiation procedures of hTGSCs, the cells were incubated with 2% (w/v) paraformaldehyde for 30 min at 4 °C for fixation. The cells were washed with PBS three times for 5 min by shaking the plates on a plate shaker. Later on, the cells were permeabilized by incubation with 0.1% (v/v) Triton X-100 (in PBS) for 5 min at room temperature followed by washing three times for 5 min with PBS. The cells were incubated with 2% (v/v) goat serum (Sigma) for 20 min at 4 °C for preventing nonspecific binding of primary antibodies. The cells were again washed three times with PBS. The cells were incubated overnight with primary antibodies at 4 °C. For osteogenic differentiation collagen type 1 (COL1A; Abcam, UK) and osteocalcin (Santa Cruz Biotechnology); for neurogenic differentiation enolase (Santa Cruz Biotechnology), nestin (Santa Cruz Biotechnology), neurofilament (NF; Santa Cruz Biotechnology), and tyrosine hydroxylase (TH; Santa Cruz Biotechnology); for adipogenic differentiation adipocyte protein 2 (αP2; Santa Cruz Biotechnology) and PPAR-γ (Abcam); for chondrogenic differentiation collagen type 2 (COL2A; Abcam); for myogenic differentiation actin (Santa Cruz Biotechnology), α-smooth muscle actin (α-SMA; Abcam), desmin (Abcam), and MyoD (Santa Cruz Biotechnology); and for odontogenic differentiation COL1A and dentin sialoprotein (DSP) (Santa Cruz Biotechnology) were used. The cells were washed three times with PBS to remove excess antibody after incubating with primary antibodies. Thereafter, the cells were treated with secondary antibodies (goat antirabbit IgG Alexa Fluor 488, goat antimouse IgG Alexa Fluor 488) and incubated for 1 h at 4 °C followed by rinsing three times with PBS. DAPI (AppliChem) was used to stain the nuclei of the cells by incubating for 20 min at 4 °C. The cells were then rinsed three times with PBS and observed under a fluorescence microscope (Nikon Eclipse TE200).
Quantitative real-time PCR
Total RNA isolation after differentiation was performed using a High Pure RNA Isolation Kit (Roche, Germany) according to the manufacturer's instructions. cDNA synthesis from isolated RNA samples was done using a High Fidelity cDNA Synthesis Kit (Roche). Real-time PCR was performed using Maxima SYBR Green/ROX (Fermentas, USA) for the determination of expression levels of differentiation-related genes after differentiations (Table) . cDNAs of the differentiated cells incubated with or without melatonin were used as templates and were mixed with primers and Maxima SYBR Green/ROX qPCR Master Mix (2X). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the house-keeping gene for the normalization of the data. All the real-time PCR experiments were performed using the iCycler RT-PCR detection system (Bio-Rad, USA).
Statistical analysis
All data are shown as the means ± standard errors. Graphics were drawn using GraphPad Prism 5 software. The results of real-time PCR data were normalized to the mRNA level of GAPDH. The statistical analysis of the results were performed by one-way ANOVA followed by the multiplecomparison Tukey test using GraphPad Prism 5 software. Statistical significance was determined at P < 0.05.
Results
Human tooth germ stem cells were characterized for the surface antigens CD29, CD34, CD45, CD73, CD90, CD105, CD133, and CD166 by flow cytometry. Cells were positive for CD29, CD73, CD90, CD105, and CD166, whereas they were negative for CD34, CD45, and CD133 ( Figure 1a ). These data showed that hTGSCs were positive for MSC markers and negative for HSC markers. Toxicity of melatonin was measured by MTS assay at various concentrations (50 nM, 100 nM, 150 nM) for days 1, 2, and 3. The results showed that melatonin was toxic to hTGSCs at none of the concentrations tested (Figure 1b) . On the contrary, it significantly increased the survival of cells at each concentration on each day compared to the negative control, except 100 nM melatonin on the 3rd day. Melatonin at 50 nM increased the survival of cells by 120%, 125%, and 110% at days 1, 2, and 3, respectively. For 100 nM melatonin, the survival rate of cells was increased by 125%, 122%, and 132% at days 1, 2, and 3, respectively.
Finally, 150 nM melatonin raised the survival by 119%, 130%, and 110% at days 1, 2, and 3, respectively ( Figure  1b) . They also expressed the two melatonin receptors, melatonin receptor 1 A (MTNR1A) and melatonin receptor 1 B (MTNR1B) (Figure 1c ). Osteogenic differentiation of hTGSCs was confirmed by von Kossa staining, immunocytochemistry, ALP activity, and quantitative real-time PCR. Von Kossa staining is a standard method to show calcium or calcium salt deposits as an indicator of osteogenic differentiation. Calcium depositions were detected by this method in cells treated with melatonin as well as in the positive control, demonstrating the osteogenic differentiation ( Figure 2a ). The expressions of osteocalcin and COL1A were visualized by immunocytochemistry. The data showed that expressions of osteocalcin and COL1A were upregulated in melatonin compared with positive control groups, whereas there was no expression in the negative control (Figure 2b ). ALP activity was measured for the determination of osteogenic differentiation (Figure 2c ). mRNA levels showed that cells treated with melatonin had the highest expression levels of these genes. Furthermore, mRNA levels of the marker genes were higher in the positive control compared to the negative control group (Figure 2d) . The expression levels of osteocalcin, ALP, and COL1A were detected significantly higher than in the positive control in the melatonin group.
Immunocytochemistry assay was performed for neuron-specific enolase (NSE), nestin, NF, and TH ( Figure  3a) . The melatonin group and the positive control were positively stained for NSE, nestin, NF, and TH, whereas the negative control did not show expressions of these marker genes. The real-time PCR results showed that the melatonin-treated group expressed the highest mRNA levels of CD133, nestin, and MAP2 compared to positive and negative controls (Figure 3b) .
For adipogenic differentiation, the expression of αP2 and PPAR-γ was checked by immunocytochemistry. Melatonin downregulated the expression of these two markers and gave a similar result to those of the negative control, while the positive control groups exhibited higher expressions of αP2 and PPAR-γ (Figure 4a ). Oil red oil is a lysochrome diazo dye used to stain lipids and neutral triglycerides. Oil red oil staining was performed to visualize the intracellular lipid vesicles after adipogenic differentiation. Lipid vesicles were detected only in the positive control (Figure 4b ). Expression levels of markers for terminal adipocyte differentiation, such as adiponectin, lipoprotein lipase (LPL), αP2, and PPAR-γ, were detected by real-time PCR. Cells treated with melatonin during adipogenic differentiation showed the lowest mRNA expressions of the all marker genes compared to positive control groups (Figure 4c ). COL2A is the main protein of articular and hyaline cartilage tissues. Expression of COL2A was checked with immunocytochemistry. Results showed that melatonin and positive control groups were positively stained, whereas the negative control showed almost no expression of COL2A (Figure 5a ). Alcian blue staining was done for the confirmation of chondrogenic differentiation. The melatonin group showed the highest amount of mucopolysaccharides and glycosaminoglycans formed in cells (Figures 5b and 5c ). mRNA levels of Sox 9, aggrecan, and COL2A were detected by real-time PCR. Melatonin groups had much higher mRNA levels of Sox 9, aggrecan, and collagen II than the positive control (Figure 5d) .
Actin, α-SMA, desmin, and MyoD were immunostained for the confirmation of myogenic differentiation of hTGSCs. Immunocytochemistry results indicate that both the melatonin group and the positive control were positively stained for actin, α-SMA, desmin, and MyoD, demonstrating the myogenic differentiation of the cells. However, the negative control showed lower expression levels of these marker genes (Figure 6a ). The myogenic markers were analyzed by real-time PCR for their expression levels to confirm the myogenic differentiation. The results indicate that all of the four marker genes were highly expressed in the melatonin groups (Figure 6b) .
The von Kossa staining method was performed to visualize the calcium deposits after odontogenic differentiation. Differentiated cells treated with melatonin as well as the positive control were positively stained, whereas the negative control did not give any positive results (Figure 7a ). COL1A and DSP were checked by immunocytochemistry to confirm the odontogenic differentiation. The melatonin group and positive control showed positive results for COL1A and DSP, whereas the negative control did not exhibit any expressions for these marker genes (Figure 7b ). ALP activity was measured for the determination of odontogenic differentiation ( Figure  7c ). For odontogenic differentiation, DSPP, COL1A, and BMP-2 were chosen as marker genes and mRNA expression levels were detected by real-time PCR. Melatonin upregulated the mRNA expression of DSPP by 1.6-fold, COL1A by 2-fold, and BMP-2 by 2.2-fold compared to the positive control (Figure 7d ). 
Discussion
The term "regenerative medicine" was first used by William A Haseltine in 2000 to describe biomedical approaches involving the replacement or regeneration of cells. Stem cells are a good candidate for regenerative medicine because of their great proliferation and differentiation capacity (Bianco and Robey, 2001 ). The source of stem cells is of great importance and is one of the major issues to be addressed since adequate numbers of stem cell are required for therapeutic use. The ideal situation is to find a source of stem cells in sufficient numbers and with high proliferation and differentiation ability as well as being easy to isolate from the body without any risk for the patient or long culture procedures. Researchers have characterized various tissues possessing stem cells with mesenchymal stem cell properties since bone marrow was identified as the first mesenchymal stem cell source (Friedenstein et al., 1976) . Bone marrow mesenchymal stem cells can be easily isolated and cultured in vitro. However, surgical procedures are required for the isolation of these cells; therefore, it has potential risks of contamination. The isolation procedure is traumatic and the number of cells obtained is limited (Campagnoli et al., 2001) . Moreover, bone marrow-related disorders are another problem for this procedure. Dental tissue seems to be a good candidate as an alternative stem cell source. Dental stem cells (DSCs) among others are more easily isolated with simple surgical access and cultivated. They are also mostly waste materials of dental procedures. Furthermore, they do not cause ethical controversies. Low morbidity in the collecting site after surgical attempts is another advantage of DSCs (Yalvac et al., 2010) . DSCs were proven to be converted to different lineages including osteogenic, odontogenic, adipogenic, and neurogenic cells and were used in some preclinical applications (Gronthos et al., 2000) .
In the current study, we used hTGSCs obtained from human third molars (wisdom teeth), which show mesenchymal stem cell characteristics, and we tested the effect of melatonin on differentiation of these cells into osteogenic, neurogenic, adipogenic, chondrogenic, myogenic, and odontogenic cells. Scientists have demonstrated that melatonin regulates the differentiation efficiency of mesenchymal stem cells. Melatonin increases osteogenic differentiation in human and mouse mesenchymal stem cells and stimulates neurogenesis in mice, whereas it suppresses the adipogenic differentiation of human mesenchymal stem cells. We chose a nontoxic concentration (50 nM) of melatonin to use in the differentiation experiments. Melatonin's effect on osteogenic differentiation of hTGSCs and the data on osteocalcin, ALP, and COL1A mRNA levels by real-time PCR and COL1A and osteocalcin immunostaining were investigated. Furthermore, von Kossa staining and ALP activity assays were performed. All the data from these experiments demonstrate that osteogenic differentiation of hTGSCs was increased by melatonin induction. This result shows similarity to a previous study in which melatonin raised the osteogenic differentiation ability of human mesenchymal stem cells. Neurogenic differentiation of hTGSCs was confirmed by real-time PCR analysis for neurogenic markers CD133, nestin, and MAP2, as well as TH, enolase, nestin, and MAP2 immunostaining. Melatonin was previously proven to upregulate the expression of neurogenic markers such as NeuroD1. In another study, it was demonstrated that melatonin increased neurogenic differentiation of neural stem cells when it was administered during the proliferation period, although it decreased neurogenic differentiation in the case of administration during the differentiation period. In contrast to this result, we showed that the neurogenic commitment of hTGSCs was elevated by melatonin when they were treated during the differentiation process. Adipogenic differentiation of hTGSCs was confirmed by the detection of mRNA levels of adiponectin, LPL, αP2, and PPAR-γ, as well as αP2 and PPAR-γ immunostaining. Lipid formation was decreased by melatonin in the melatonin group compared to the positive control. These results, including the immunocytochemical data, prove that melatonin reduces adipogenic differentiation of hTGSCs. These results are similar to a previous study in which the adipogenic conversion of mesenchymal stem cells were inhibited by melatonin treatment.
Chondrogenic differentiation was confirmed by realtime PCR analysis of Sox 9, aggrecan, and COL2A as well as immunocytochemistry for COL2A. Chondrogenic results prove that melatonin also increases the chondrogenic differentiation of hTGSCs. Melatonin was also tested for its effect on the myogenic differentiation of hTGSCs. Although melatonin is discovered to enhance the survival of myocytes, it is still unclear whether it has a potential effect on the myogenic differentiation of mesenchymal stem cells. In this study, we show that it raises the myogenic conversion of hTGSCs, which have mesenchymal stem cell properties. Finally, odontogenic differentiation was determined by measuring mRNA levels of DSPP, COL1A, and BMP-2 by real-time PCR analysis, immunostaining of COL1A and DSP, and von Kossa staining to observe calcium depositions. It was concluded that melatonin also raised odontogenic efficiency of hTGSCs. For the first time, melatonin's effect on odontogenic differentiation was shown in this study. In conclusion, melatonin increased osteogenic, neurogenic, chondrogenic, myogenic, and odontogenic differentiation of hTGSCs, whereas it inhibited adipogenic differentiation. The osteogenic and adipogenic differentiation of mesenchymal stem cells are dependent on certain lineage-specific transcription factors. These factors determine whether cells will enter bone or fat cell lineages. PPAR-γ and the CCAAT/enhancer-binding protein (C/ EBP) family regulate adipogenic differentiation while Runx2 and osterix regulate osteogenic differentiation.
The relationship between PPAR-γ and Runx2 is crucial for leading mesenchymal stem cells to osteogenic or adipogenic commitment. It has been shown that the high expression of PPAR-γ decreases the expression of Runx2 while low expression of PPAR-γ decreases adipogenesis and increase osteogenesis.
In our study, it was found that PPAR-γ was downregulated in the treatment of melatonin. However, Runx2 expression in differentiated hTGSCs is also needed to be investigated to better understand whether there is the same regulation system between Runx2 and PPAR-γ. The relationship between osteogenic and adipogenic determination is especially important for osteoporosis, in which bone formation is accompanied by elevated adipogenesis in bone marrow. Based on our results, melatonin might be a good candidate as a drug for preventing osteoporosis. Besides its various roles in the human body, the use of melatonin increases the possibility of success in regenerative therapy applications since it increases the survival of cells as well as supports the differentiation of them. Moreover, hTGSCs are a good stem cell source for a number of reasons, such as having mesenchymal stem cell properties, being a waste material with no contamination risk, causing no ethical issues, and having an easy isolation procedure. In this study, we found that melatonin increases the differentiation abilities of hTGSCs. In the future, it might be possible to use melatonin as a drug due to its promoting effects on stem cells for the treatment of many disorders involving cell or tissue damage such as neurodegenerative diseases, degenerative muscle diseases, diabetes, and osteoporosis. 
